Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.
Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, León A, Arnaiz C, Navarro G, Páramo MD, Cuesta A, Soria B, Hmadcha A, Pozo D, Fernandez-Montesinos R, Leal M, Ochotorena I, Gálvez P, Geniz MA, Barón FJ, Mata R, Medina C, Caparrós-Escudero C, Cardesa A, Cuende N; Research Group Study EudraCT 2008-004015-35. Fernández O, et al. Among authors: reyes v. PLoS One. 2018 May 16;13(5):e0195891. doi: 10.1371/journal.pone.0195891. eCollection 2018. PLoS One. 2018. PMID: 29768414 Free PMC article. Clinical Trial.
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment.
Aliaga-Gaspar P, Hurtado-Guerrero I, Ciano-Petersen NL, Urbaneja P, Brichette-Mieg I, Reyes V, Rodriguez-Bada JL, Alvarez-Lafuente R, Arroyo R, Quintana E, Ramió-Torrentà L, Alonso A, Leyva L, Fernández O, Oliver-Martos B. Aliaga-Gaspar P, et al. Among authors: reyes v. Front Immunol. 2021 Dec 16;12:778204. doi: 10.3389/fimmu.2021.778204. eCollection 2021. Front Immunol. 2021. PMID: 34975865 Free PMC article.
Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations.
Ciano-Petersen NL, Aliaga-Gaspar P, Hurtado-Guerrero I, Reyes V, Rodriguez-Bada JL, Rodriguez-Traver E, Brichette-Mieg I, Leyva Fernández L, Serrano-Castro P, Alonso A, Oliver-Martos B. Ciano-Petersen NL, et al. Among authors: reyes v. Front Immunol. 2023 Aug 22;14:1242508. doi: 10.3389/fimmu.2023.1242508. eCollection 2023. Front Immunol. 2023. PMID: 37675113 Free PMC article.
Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial.
Steel JL, George CJ, Terhorst L, Yabes JG, Reyes V, Zandberg DP, Nilsen M, Kiefer G, Johnson J, Marsh C, Bierenbaum J, Tageja N, Krauze M, VanderWeele R, Goel G, Ramineni G, Antoni M, Vodovotz Y, Walker J, Tohme S, Billiar T, Geller DA. Steel JL, et al. Among authors: reyes v. Lancet. 2024 Apr 6;403(10434):1351-1361. doi: 10.1016/S0140-6736(24)00015-1. Epub 2024 Mar 12. Lancet. 2024. PMID: 38490230 Clinical Trial.
A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2.
Shaverdashvili K, Reyes V, Wang H, Mehta D, Marsh C, Waas JK, VanderWeele RA, Peracha SM, Liang H, Socinski MA, Gerber DE, Dowell JE, Villaruz LC. Shaverdashvili K, et al. Among authors: reyes v. EClinicalMedicine. 2023 Nov 21;66:102317. doi: 10.1016/j.eclinm.2023.102317. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192592 Free PMC article.
Addressing the unmet needs in patients with type 2 inflammatory diseases: when quality of life can make a difference.
Gómez de la Fuente E, Alobid I, Ojanguren I, Rodríguez-Vázquez V, Pais B, Reyes V, Espinosa M, Luca de Tena Á, Muerza I, Vidal-Barraquer E. Gómez de la Fuente E, et al. Among authors: reyes v. Front Allergy. 2023 Nov 9;4:1296894. doi: 10.3389/falgy.2023.1296894. eCollection 2023. Front Allergy. 2023. PMID: 38026127 Free PMC article.
295 results